GlassScriptPhysician profile
Colleen M Walker
NPI 1750346078
$2,210.00
in general payments reported to CMS, 2019-2025
23 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.62 · 2020: $16.59 · 2021: $171 · 2022: $261 · 2023: $529 · 2024: $665 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $361.13 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $183.55 | 2023-2025 | Sunosi, Auvelity |
| Glaxosmithkline, LLC. | $144.01 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $143.53 | 2022-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $93.04 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $92.84 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $71.54 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $68.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $61.24 | 2019-2024 | |
| Inspire Medical Systems, INC. | $57.61 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $38.30 | 2023-2024 | Quviviq |
| Pfizer INC. | $33.86 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.89 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $30.26 | 2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $29.63 | 2024 | |
| Insulet Corporation | $24.61 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $20.55 | 2021 | |
| Vivus LLC | $19.77 | 2024 | Pancreaze |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2025 | Rexulti |
| Philips North America LLC | $18.47 | 2025 | Extended Holter |
| Tolmar, INC. | $15.75 | 2024 | |
| Astellas Pharma US INC | $13.92 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.